Polypharmacy and Major Adverse Events in Atrial Fibrillation.
J Cardiovasc Pharmacol
; 80(6): 781-782, 2022 12 01.
Article
en En
| MEDLINE
| ID: mdl-36027584
ABSTRACT
ABSTRACT Atrial fibrillation is the most common arrhythmia, ranging from 0.1% in patients <55 years to >9% in octogenarian patients. Polypharmacotherapy is crucial in atrial fibrillation management, and in many of the concomitant comorbidities, such as hypertension, heart failure, coronary artery disease, and diabetes. However, polypharmacy represents a major concern because of the associated risks of adverse events onset, with an increased risk of all-cause mortality and cardiovascular mortality. In this study, we commented data reported by Tsagkaris et al comparing them with previous reports.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Fibrilación Atrial
Límite:
Aged80
/
Humans
Idioma:
En
Revista:
J Cardiovasc Pharmacol
Año:
2022
Tipo del documento:
Article
País de afiliación:
Italia